CooperCompanies (COO) Q2 2026 earnings review
Record Adjusted Earnings Overshadowed by $272M Recall Charge
CooperCompanies delivered a mixed Q2. The adjusted operational execution was outstanding: Non-GAAP EPS surged 26% as operating margins expanded by 260 basis points. However, the GAAP bottom line collapsed to a $78M loss, driven by a massive $272M litigation charge tied to the CooperSurgical fertility media recall. Management noted that reaching agreements to resolve these claims unlocks the ability to move forward with their ongoing strategic review. Beneath the surface, segment trends are reversing: the previously struggling Fertility business accelerated to 10% organic growth, while the core CooperVision (CVI) engine showed signs of fatigue, prompting a downgrade in full-year CVI revenue guidance.
🐂 Bull Case
Non-GAAP operating margin expanded 260 basis points year-over-year to 27%. Synergies from the fiscal 2025 reorganization are flowing straight to the bottom line, allowing the company to maintain its full-year EPS guidance despite lowering revenue expectations.
The Fertility segment is reversing its prior weakness, accelerating to 10% organic growth in Q2. This is a massive improvement from the 1-3% growth rates seen throughout 2025.
🐻 Bear Case
CooperVision (CVI) full-year organic growth guidance was cut from 4.5-5.5% down to 3.5-4.5%. Sphere contact lenses grew a sluggish 1% organically, indicating core volume fatigue.
Due to the $324.8M accrued litigation liability, capital returns were abruptly paused. Share buybacks collapsed to just $13.1M in Q2, contradicting prior management claims of allocating two-thirds of free cash flow to repurchases.
⚖️ Verdict: ⚪
Neutral. The operational margin execution is flawless and settling the fertility litigation clears a major overhang. However, a downgrade to the core CooperVision revenue engine and a near-halt in share repurchases prevent a bullish rating.
Key Themes
CooperVision Growth Trajectory Decelerating
Management's narrative of consistent market-beating contact lens growth is cracking. While CVI reported 4% organic growth in Q2, the underlying Sphere category grew only 1%. More importantly, management cut full-year CVI organic growth guidance from a midpoint of 5.0% down to 4.0%. This confirms that the APAC/Japan weakness identified in Q1 is not resolving as quickly as anticipated, and new private label contracts are failing to completely offset the drag.
Fertility Segment Turnaround
Reversing a multi-quarter trend of stagnation, the CooperSurgical (CSI) Fertility segment posted an impressive 10% organic growth rate in Q2 (up from 3% in Q1 and 1% in 25Q4). This suggests that the prolonged period of clinical destocking and delayed capital equipment purchases in global IVF markets is ending, restoring a vital growth engine for the CSI division.
Relentless Margin Expansion
The standout metric of the quarter is the non-GAAP operating margin, which expanded from 24.4% to 27%. The company successfully executed its late-2025 reorganization. Despite ongoing macro pressures and rising tariff costs, Cooper Companies entirely offset these headwinds through disciplined fixed-cost leverage and positive foreign exchange impacts, resulting in a 26% spike in non-GAAP EPS.
Litigation Liability Paralyzes Buybacks
While management framing paints the $271.6M litigation charge (related to the December 2023 embryo culture media recall) as a necessary step to 'move forward,' the financial toll is severe. The balance sheet now shows a $324.8M current accrued litigation liability. Consequently, share buybacks plummeted to a negligible $13.1M in Q2, down from $92M in Q1 and $197M in 25Q4. The previously promised aggressive capital return strategy is now effectively frozen until this cash exits the door.
Toric and Multifocal Lenses Anchor CVI
While standard spherical lenses flatlined (1% growth), CooperVision's specialty portfolio of Toric and Multifocal lenses provided much-needed stability, growing 7% organically to $364.9M. This continues to validate the company's technical superiority in complex lens designs, which command higher price points and stickier patient retention.
Strategic Review Nearing Conclusion?
CEO Al White explicitly stated that reaching the settlement framework for the fertility media recall represents an 'important step' allowing the company to 'move forward with our strategic review.' With the primary legal tail-risk quantified and ring-fenced, the board now has a clean path to either announce a formal split of the CooperVision and CooperSurgical businesses or definitively commit to the current structure.
Other KPIs
Decelerating. Cash provided by operations of $182.8M was offset by $86.4M in CapEx. This is a sharp drop from the $159M in FCF generated in Q1. The litigation accruals have not yet been fully paid out in cash, meaning future quarters will see further cash flow suppression as these settlements are funded.
Accelerating. The EMEA region was the geographic standout for the contact lens business, surging 17% reported and 6% organically. This outpaced the Americas (+7% organic) and significantly offset the ongoing contraction in Asia Pacific (-6% organic).
Guidance
Decelerating. Management cut the top end of their organic growth expectation, lowering the range from 4.5-5.5% down to 3.5-4.5%. This explicitly signals that the Q1 headwinds are persisting longer than originally forecasted.
Decelerating. Organic growth guidance was lowered to 3.5-4.5% (down from 4.5-5.5% previously). This contradicts the narrative from prior quarters that Q1 weakness in APAC was an isolated timing issue, indicating broader structural or competitive drag in the contact lens market.
Stable. Organic growth guidance maintained at 4-5%. The strong 10% organic growth in Fertility in Q2 provides a high degree of confidence that this segment will comfortably achieve or beat its annual targets.
Stable. The company maintained its full-year earnings target despite lowering the revenue outlook. This is a testament to the aggressive operating expense discipline and the success of the Q4 reorganization, allowing them to protect bottom-line commitments.
Key Questions
Anatomy of the CVI Guidance Cut
With CVI organic growth guidance lowered by a full percentage point, is the weakness entirely contained to the previously disclosed APAC legacy products, or are you seeing new deceleration in the Americas/EMEA daily silicone hydrogel conversion rates?
Buyback Freeze
Share repurchases dropped to just $13M this quarter. Is this capital preservation strictly tied to funding the $324M litigation liability, and should investors expect repurchases to remain negligible until these settlements are paid out?
Strategic Review Timing
Now that the fertility media litigation is substantially quantified and provisioned for, does this remove the final internal barrier to concluding and announcing the results of the corporate strategic review?
Fertility Acceleration Durability
Fertility organic growth spiked to 10%. How much of this was catch-up from delayed clinic CapEx versus a structural increase in global IVF cycle volumes?